COMMUNIQUÉS West-GlobeNewswire

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
14/10/2026
-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- ATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys [...]
Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
14/10/2026
CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo ® Lumbar Bi-lateral Posterior System at the North [...]
Imprivata’s Access Intelligence Platform Wins Cybersecurity Breakthrough Award for Second Consecutive Year
14/10/2026
Access Intelligence Platform named 2026 IoT Security Analytics Solution of the Year, reinforcing its impact on secure, efficient access workflows WALTHAM, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading [...]
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
14/10/2026
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster [...]
Parexel to Spotlight Site Partnership, Innovation & Industry-Leading Site Performance at 2026 Society for Clinical Research Sites (SCRS) Global Site Solutions Summit™
14/10/2026
Company brings its expertise in driving faster site activation and enrollment and better patient retention to panel discussions; continues commitment to helping sites navigate growing trial complexity Company also [...]
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™
14/10/2026
Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro Initial engagement marks QCi's first [...]
Cannabix Technologies Files Provisional Patent Application for BCU-Enabled Point-of-Care Marijuana Breath Testing
14/10/2026
VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing [...]
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
14/10/2026
Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award [...]
Family Medicine Forum, Canada’s largest family medicine celebration, returns to Toronto this November
14/10/2026
Celebrating family medicine with four days of learning, networking, and events MISSISSAUGA, Ontario, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Family Medicine Forum (FMF) is back in Toronto, November 11th to 14th, for four days [...]
Le Forum en médecine familiale, le plus grand rassemblement de médecins de famille au Canada, revient à Toronto en novembre!
14/10/2026
Célébrez la médecine de famille avec quatre jours d’apprentissage, de réseautage et d’événements MISSISSAUGA, Ontario, 14 oct. 2026 (GLOBE NEWSWIRE) -- Le Forum en médecine familiale (FMF) est de retour à Toronto, du 11 [...]
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
14/10/2026
Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction NOVATO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE [...]
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
14/10/2026
Scientific Reports Paper Shows Synergistic Trypsinogen/Chymotrypsinogen A Combination (1:6) Inhibits Angiogenesis, Migration, Invasion and EMT While Delivering Significant Tumor Reduction in Orthotopic Models and [...]
Prodeon Medical Announces First Commercial Case of the Urocross® Expander System
14/10/2026
First procedure at The Hospital at Westlake Medical Center in Austin, Texas, marks the beginning of the company’s controlled U.S. commercial release SAN JOSE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prodeon Medical , [...]
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
14/10/2026
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Rad Source Launches AccuTag™ Blood Irradiation Indicators Ahead of AABB 2026
14/10/2026
White-to-blue indicator gives blood banks visual confirmation of the 15 Gy minimum at a 25 Gy target dose, on display at Booth 1314 BUFORD, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rad Source Technologies, Inc. (Rad [...]
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
14/10/2026
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
14/10/2026
Dr. O’Malley brings deep immunology clinical development expertise, with previous leadership roles at CRISPR Therapeutics and Sanofi Appointment follows Matchpoint’s recent $150M Series B financing to advance pipeline [...]
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
14/10/2026
FDA’s Rare Disease Evidence Principles ( RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance enables engagement with [...]
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
14/10/2026
-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate [...]

Pages